Innoviva Q2 2023: GSK royalties $65.7M, XACDURO FDA approved, net income $1.3M

Innoviva, Inc.

2023-Q2 EPS reported $0.46 revenue$157,364,000

GSK royalties of $65.7M (RELVAR/BREO $54.4M, ANORO $11.3M) vs $111.7M in Q2 2022 due to TRELEGY royalty sale.
Net product sales $15.7M (GIAPREZA $11.2M, XERAVA $4.5M); $3.0M license milestone from XACDURO FDA approval.
Net income $1.3M ($0.02 basic EPS) vs $0.9M ($0.01) in Q2 2022; cash + receivables $254M.
Repurchased 775,504 shares for $9.2M in Q2 2023; invested $25M in Armata (NYSE: ARMP) on July 11, 2023.
On May 23, 2023, FDA approved XACDURO for HABP/VABP caused by Acinetobacter; launch expected H2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.7

Innoviva, Inc. reported the second quarter ended June 30, 2023 results: net income $1.3 million, or $0.02 basic per share, EPS $0.02 basic per share.

Period: the second quarter ended June 30, 2023
Net income: $1.3 million, or $0.02 basic per share
EPS: $0.02 basic per share
Result: reported results

Exact text from the filing

Innoviva, Inc. (the "Company") issued a press release regarding its results of operations and financial condition for the quarter ended June 30, 2023.

View on SEC.gov

Browse all earnings releases →

Innoviva, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-086806

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.